1 郭瑞臣, 王德全, 董明, 等.糖尿病人N-乙酰化表型研究.中国临床药理学杂志, 1998;14(3): 146
2 Guo RC, Sun RP, Cui X.Distribution of N-acetylate phenotype in Chinese children and its relationship with down’s sy ndrome and duchenne muscular dystrophy. Chin J Clin Pharmacol Ther, 1999; 4(1): 17
3 Guo RC, Wolfgang T, Bernhard L.The relationship between high incidence of adverse dapsone reaction in Aids patients and slow acety lator phenoty peorlow plasma/ lymphocy tesglutathio ne level of these patients. Chin Med J(Eng l), 1996; 109(12): 933
4 Lee BL.Adverse reactions to trimethoprim-sulfamethox azole. Clin Rev Allergy Immunol, 1997; 14(4): 451
5 Schops W, Prior V, Golka K, et al. Clinical relevance of acety lator phenol typing in 196 urothelial tumor patients. Urologe A, 1997; 36(1): 64
6 刘丽娟, 李军, 郭瑞臣, 等.肝病患者药物代谢酶细胞色素P450酶1A2、多态性N-乙酰化酶、黄嘌呤酶活性的变化.中国医院药学杂志, 2000;20(4): 212
7 Weber WW. N-acetylation phamacogenetics. Pharmacol Rev, 1985;37: 25
8 Risch A, Wallace DM, athers S, et al. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum Mol Genet, 1995; 4(2): 231
9 Kloth MT, Gee Rl, Messing EM, et al. Expression of NAT in cultured human uroepithelial cells.Carcinogenesis, 1994; 15(12): 2781
10 谢红光, 周宏灏.药物乙酰化遗传多态性的现状与展望.湖南医学, 1993; 10(3): 159
11 Graf T, Broly F, Hoffman F, et al. Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers. Eur J Clin Pharmacol, 1992;43: 399
12 Blum M, Demierre A, Grant DM, et al. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci, 1991; 88: 5237
13 Deguchi T, Mashimo M, Suzuki T. Correlation between acetylator phenotypes and genotypes of polymorphic arylamine NAT in human liver. J Biol Chem, 1990; 265(22): 12757
14 郭瑞臣, 崔唏, 王本杰, 等.国人乙酰化表型测定研究(附203例报告). 山东医科大学学报, 1997; 35(4): 344
15 Hein DW.Polymorphic expression of NAT activity in the inbred hamster. Fred Proc, 1984; 43:934
16 Glowinsgki IB, Weber WW.Biochemical charaterization of geneti-cally various aromatic amine NAT in A/ J and C57 BL/ 6J mice. J Biol Chem. , 1982; 257: 1431
17 Hein DW.Biochemical evidence for the coexistence of monomorphic and polymorphic NAT activity o n a common protein in rabbit liver. J Phmarcol Exp Ther, 1982;220: 1
18 安国升. 人群N-乙酰化表型研究.临床药学, 1993;2(4): 41
19 Hayes RB, Bi W, Rothman W, et al. N-Acetylation phenotype and genotype and risk of bladder cancer in bezidineexposed workers. Carcinogenesis, 1993;14(4): 675
20 谢红光, 周宏灏.中国主要民族乙酰化能力的遗传流行特征.药物流行病学, 1995; 4(2): 41
21 Kadluber FF, Butler MA, Kaderlic KR, et al. Polymophisms for aromatic amine metabolism in humans: relevance for human carcinogenesis. Environ Health Perspect, 1992; 98: 69
22 Lower GW, Nilsson T, Nelson CE, et al. N-Acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology Preliminary results in Sweden and Denmark. Environ Health Perspect, 1979; 29: 71
23 Wang CY, Zukowski K, Flammang TJ, et al. Production of urothelial tumors in the hetero topic bladder of rat by bezidine derivatives. Cancer Res, 1990;50: 2868
24 郭瑞臣, 崔唏, 徐祗顺, 等.乙酰化代谢表型与膀胱癌关系的研究.中国临床药理学杂志, 1997; 13(3): 139
25 Cartw right RA, Glasham RW, Rogers HT, et al. The role of NAT phenotype in bladder carcinogenesis: a pharmacogenetic epidemiologic approach to bladder cancer. Lancet, 1982; ii: 842
26 Orzechowska JK, Niewinski P, Pawlik J, et al. Genetically determined spartein oxidation and sulfadimidine acetylation n polymorphism in patients with no n-occupational urinary bladder cancer. Mater Med Pol, 1994; 26(4): 145 |
